Download PDF
Semin Respir Crit Care Med 2017; 38(05): 701-710
DOI: 10.1055/s-0037-1606223
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Lung Transplantation for Pulmonary Hypertension and Strategies to Bridge to Transplant

Timothy J. Baillie
1   Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2   Division of Respirology, University Health Network, Mount Sinai Hospital, Women's College Hospital, Toronto, Ontario, Canada
,
John T. Granton
1   Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2   Division of Respirology, University Health Network, Mount Sinai Hospital, Women's College Hospital, Toronto, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
15 October 2017 (online)

    Permissions and Reprints

Abstract

Despite an expanded armamentarium of medical therapies, pulmonary arterial hypertension (PAH) remains a progressive disease associated with significant morbidity and premature mortality. Lung transplantation (LT) is the last safety net for patients failing medical therapy, providing excellent overall long-term survival and health-related quality-of-life outcomes in line with more common parenchymal lung disease indications. Waitlist mortality remains disproportionally elevated, however, reflecting an inability of the lung allocation score to completely capture PAH disease severity, and a propensity for PAH to deteriorate rapidly without warning, even in patients who appear externally “well.” Early referral to a LT center can mitigate these risks and facilitate rapid listing if necessary. Several bridging therapies are available to support severely unwell patients to LT, such as extracorporeal life support (ECLS) and atrial septostomy. Unique perioperative considerations include higher rates of primary graft dysfunction and dynamic right ventricular outflow obstruction which may, at least in part, reflect rapid afterload reduction in the face of a conditioned right ventricle. Extending ECLS into the perioperative period may ameliorate these risks by allowing more gradual adaptation of both ventricles to their new loading conditions. Chronic lung allograft dysfunction, particularly bronchiolitis obliterans syndrome, remains a major cause of long-term morbidity and mortality, and complications from corticosteroid and immunosuppressive therapy are common. Nevertheless, the morbidity, mortality, and burden of disease management after LT continue to improve and compare favorably to that of refractory PAH in carefully selected patients.

Keywords

lung - extracorporeal membrane - lung transplantation - allografts - pulmonary arterial hypertension - heart - ventricles
 

  • References

  • 1 McGoon MD, Benza RL, Escribano-Subias P. , et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62 (25, Suppl): D51-D59
    CrossrefPubMedGoogle Scholar
  • 2 Humbert M, Sitbon O, Chaouat A. , et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 (02) 156-163
    CrossrefPubMedGoogle Scholar
  • 3 Campo A, Mathai SC, Le Pavec J. , et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182 (02) 252-260
    CrossrefPubMedGoogle Scholar
  • 4 Benza RL, Miller DP, Gomberg-Maitland M. , et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (02) 164-172
    CrossrefPubMedGoogle Scholar
  • 5 D'Alonzo GE, Barst RJ, Ayres SM. , et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (05) 343-349
    CrossrefPubMedGoogle Scholar
  • 6 Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010; 31 (17) 2080-2086
    CrossrefPubMedGoogle Scholar
  • 7 Kemp K, Savale L, O'Callaghan DS. , et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012; 31 (02) 150-158
    CrossrefPubMedGoogle Scholar
  • 8 Sitbon O, Jaïs X, Savale L. , et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43 (06) 1691-1697
    CrossrefPubMedGoogle Scholar
  • 9 Galiè N, Barberà JA, Frost AE. , et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
    CrossrefPubMedGoogle Scholar
  • 10 Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013; 32 (11) 1114-1122
    CrossrefPubMedGoogle Scholar
  • 11 Tonelli AR, Arelli V, Minai OA. , et al. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 188 (03) 365-369
    CrossrefPubMedGoogle Scholar
  • 12 Galiè N, Humbert M, Vachiery JL. , et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (01) 67-119
    CrossrefPubMedGoogle Scholar
  • 13 Nickel N, Golpon H, Greer M. , et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39 (03) 589-596
    CrossrefPubMedGoogle Scholar
  • 14 Miller DP, Farber HW. “Who'll be the next in line?” The lung allocation score in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2013; 32 (12) 1165-1167
    CrossrefPubMedGoogle Scholar
  • 15 Galiè N, Corris PA, Frost A. , et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D60-D72
    CrossrefPubMedGoogle Scholar
  • 16 George MP, Champion HC, Pilewski JM. Lung transplantation for pulmonary hypertension. Pulm Circ 2011; 1 (02) 182-191
    CrossrefPubMedGoogle Scholar
  • 17 Orens JB, Estenne M, Arcasoy S. , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (07) 745-755
    CrossrefPubMedGoogle Scholar
  • 18 Egan TM, Murray S, Bustami RT. , et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6 (5, Pt 2): 1212-1227
    CrossrefPubMedGoogle Scholar
  • 19 Gottlieb J, Greer M, Sommerwerck U. , et al. Introduction of the lung allocation score in Germany. Am J Transplant 2014; 14 (06) 1318-1327
    CrossrefPubMedGoogle Scholar
  • 20 Eurotransplant. Introduction of the LAS in the Netherlands. Eurotransplant; 2014
    PubMedGoogle Scholar
  • 21 NHSBT. Donor Lung Distribution and Allocation. 2017 . Policy 230/7, URL: http://odt.nhs.uk/pdf/lung_allocation_policy.pdf
    PubMed
  • 22 The Transplantation Society of Australia and New Zealand. Organ Transplantation from Deceased Donors: Consensus Statement on Eligibility Criteria and Allocation Protocols. 2011
    PubMed
  • 23 Chen F, Oga T, Yamada T. , et al. Lung allocation score and health-related quality of life in Japanese candidates for lung transplantation. Interact Cardiovasc Thorac Surg 2015; 21 (01) 28-33
    CrossrefPubMedGoogle Scholar
  • 24 Davis SQ, Garrity Jr ER. Organ allocation in lung transplant. Chest 2007; 132 (05) 1646-1651
    CrossrefPubMedGoogle Scholar
  • 25 Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States. J Heart Lung Transplant 2016; 35 (04) 433-439
    CrossrefPubMedGoogle Scholar
  • 26 Singer JP, Katz PP, Soong A. , et al. Effect of lung transplantation on health-related quality of life in the era of the lung allocation score: a U.S. prospective cohort study. Am J Transplant 2017; 17 (05) 1334-1345
    CrossrefPubMedGoogle Scholar
  • 27 Yusen RD, Edwards LB, Dipchand AI. , et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant 2016; 35 (10) 1170-1184
    CrossrefPubMedGoogle Scholar
  • 28 Chen H, Shiboski SC, Golden JA. , et al. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med 2009; 180 (05) 468-474
    CrossrefPubMedGoogle Scholar
  • 29 Gomberg-Maitland M, Glassner-Kolmin C, Watson S. , et al. Survival in pulmonary arterial hypertension patients awaiting lung transplantation. J Heart Lung Transplant 2013; 32 (12) 1179-1186
    CrossrefPubMedGoogle Scholar
  • 30 Benza RL, Miller DP, Frost A, Barst RJ, Krichman AM, McGoon MD. Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry. Transplantation 2010; 90 (03) 298-305
    PubMedGoogle Scholar
  • 31 OPAT Network. Policies, Effective Date 06/29/2017. URL: https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_10
    PubMed
  • 32 Keogh AM, Mayer E, Benza RL. , et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S67-S77
    CrossrefPubMedGoogle Scholar
  • 33 de Perrot M, Granton JT, McRae K. , et al. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. J Heart Lung Transplant 2011; 30 (09) 997-1002
    CrossrefPubMedGoogle Scholar
  • 34 Dellgren G, Riise GC, Swärd K. , et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation: a long-term study. Eur J Cardiothorac Surg 2015; 47 (01) 95-100 , discussion 100
    CrossrefPubMedGoogle Scholar
  • 35 Javidfar J, Brodie D, Iribarne A. , et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation and recovery. J Thorac Cardiovasc Surg 2012; 144 (03) 716-721
    CrossrefPubMedGoogle Scholar
  • 36 Del Sorbo L, Boffini M, Rinaldi M, Ranieri VM. Bridging to lung transplantation by extracorporeal support. Minerva Anestesiol 2012; 78 (02) 243-250
    PubMedGoogle Scholar
  • 37 Abrams DC, Brodie D, Rosenzweig EB, Burkart KM, Agerstrand CL, Bacchetta MD. Upper-body extracorporeal membrane oxygenation as a strategy in decompensated pulmonary arterial hypertension. Pulm Circ 2013; 3 (02) 432-435
    CrossrefPubMedGoogle Scholar
  • 38 Gulack BC, Hirji SA, Hartwig MG. Bridge to lung transplantation and rescue post-transplant: the expanding role of extracorporeal membrane oxygenation. J Thorac Dis 2014; 6 (08) 1070-1079
    PubMedGoogle Scholar
  • 39 Lehmann S, Uhlemann M, Leontyev S. , et al. Fate of patients with extracorporeal lung assist as a bridge to lung transplantation versus patients without--a single-center experience. Perfusion 2015; 30 (02) 154-160
    CrossrefPubMedGoogle Scholar
  • 40 Roussel A, Al-Attar N, Khaliel F. , et al. Arterial vascular complications in peripheral extracorporeal membrane oxygenation support: a review of techniques and outcomes. Future Cardiol 2013; 9 (04) 489-495
    CrossrefPubMedGoogle Scholar
  • 41 Aziz F, Brehm CE, El-Banyosy A, Han DC, Atnip RG, Reed AB. Arterial complications in patients undergoing extracorporeal membrane oxygenation via femoral cannulation. Ann Vasc Surg 2014; 28 (01) 178-183
    CrossrefPubMedGoogle Scholar
  • 42 Javidfar J, Brodie D, Sonett J, Bacchetta M. Venovenous extracorporeal membrane oxygenation using a single cannula in patients with pulmonary hypertension and atrial septal defects. J Thorac Cardiovasc Surg 2012; 143 (04) 982-984
    CrossrefPubMedGoogle Scholar
  • 43 Strueber M, Hoeper MM, Fischer S. , et al. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am J Transplant 2009; 9 (04) 853-857
    CrossrefPubMedGoogle Scholar
  • 44 Patil NP, Mohite PN, Reed A, Popov AF, Simon AR. Modified technique using Novalung as bridge to transplant in pulmonary hypertension. Ann Thorac Surg 2015; 99 (02) 719-721
    CrossrefPubMedGoogle Scholar
  • 45 Fischer S, Simon AR, Welte T. , et al. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg 2006; 131 (03) 719-723
    CrossrefPubMedGoogle Scholar
  • 46 Mayes J, Niranjan G, Dark J, Clark S. Bridging to lung transplantation for severe pulmonary hypertension using dual central Novalung lung assist devices. Interact Cardiovasc Thorac Surg 2016; 22 (05) 677-678
    CrossrefPubMedGoogle Scholar
  • 47 Fuehner T, Kuehn C, Hadem J. , et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med 2012; 185 (07) 763-768
    CrossrefPubMedGoogle Scholar
  • 48 Rosenzweig EB, Chicotka S, Bacchetta M. Right ventricular assist device use in ventricular failure due to pulmonary arterial hypertension: lessons learned. J Heart Lung Transplant 2016; 35 (10) 1272-1274
    CrossrefPubMedGoogle Scholar
  • 49 Bein T, Weber F, Philipp A. , et al. A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med 2006; 34 (05) 1372-1377
    CrossrefPubMedGoogle Scholar
  • 50 Iacono A, Groves S, Garcia J, Griffith B. Lung transplantation following 107 days of extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 2010; 37 (04) 969-971
    CrossrefPubMedGoogle Scholar
  • 51 Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 52 Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15 (1, Pt 1): 100-105
    PubMedGoogle Scholar
  • 53 Sandoval J, Gomez-Arroyo J, Gaspar J, Pulido-Zamudio T. Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments. J Cardiol 2015; 66 (04) 304-314
    CrossrefPubMedGoogle Scholar
  • 54 Sandoval JTA. The right ventricle in health and disease: atrial septostomy. In: Voelkel NF, Schranz D. , eds. The Right Ventricle in Health and Disease. New York, NY: Springer; 2015: 419-437
    Google Scholar
  • 55 Zierer A, Melby SJ, Voeller RK, Moon MR. Interatrial shunt for chronic pulmonary hypertension: differential impact of low-flow vs. high-flow shunting. Am J Physiol Heart Circ Physiol 2009; 296 (03) H639-H644
    CrossrefPubMedGoogle Scholar
  • 56 Austen WG, Morrow AG, Berry WB. Experimental studies of the surgical treatment of primary pulmonary hypertension. J Thorac Cardiovasc Surg 1964; 48: 448-455
    PubMedGoogle Scholar
  • 57 Weimar T, Watanabe Y, Kazui T. , et al. Impact of differential right-to-left shunting on systemic perfusion in pulmonary arterial hypertension. Catheter Cardiovasc Interv 2013; 81 (05) 888-895
    CrossrefPubMedGoogle Scholar
  • 58 Chiu JS, Zuckerman WA, Turner ME. , et al. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes. J Heart Lung Transplant 2015; 34 (03) 376-380
    CrossrefPubMedGoogle Scholar
  • 59 Potts WJ, Smith S, Gibson S. Anastomosis of the aorta to a pulmonary artery in certain types of congenital heart disease. Case Rep Child Meml Hosp Chic 1946; 5 (12) 704-718
    PubMedGoogle Scholar
  • 60 Blanc J, Vouhé P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med 2004; 350 (06) 623
    CrossrefPubMedGoogle Scholar
  • 61 Baruteau AE, Serraf A, Lévy M. , et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Ann Thorac Surg 2012; 94 (03) 817-824
    CrossrefPubMedGoogle Scholar
  • 62 Kim SH, Jang WS, Lim HG, Kim YJ. Potts shunt in patients with primary pulmonary hypertension. Korean J Thorac Cardiovasc Surg 2015; 48 (01) 52-54
    CrossrefPubMedGoogle Scholar
  • 63 Fiszer R, Karwot B, Chodór B. , et al. Potts' shunt in a child with idiopathic pulmonary arterial hypertension - one-and-a-half year observation. Kardiochir Torakochirurgia Pol 2015; 12 (02) 170-172
    PubMedGoogle Scholar
  • 64 Grady RM, Eghtesady P. Potts shunt and pediatric pulmonary hypertension: what we have learned. Ann Thorac Surg 2016; 101 (04) 1539-1543
    CrossrefPubMedGoogle Scholar
  • 65 Baruteau AE, Belli E, Boudjemline Y. , et al. Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. Eur J Cardiothorac Surg 2015; 47 (03) e105-e110
    CrossrefPubMedGoogle Scholar
  • 66 Keogh AM, Nicholls M, Shaw M, Dhital K, Weintraub R, Winlaw DS. Modified Potts shunt in an adult with pulmonary arterial hypertension and recurrent syncope - three-year follow-up. Int J Cardiol 2015; 182: 36-37
    CrossrefPubMedGoogle Scholar
  • 67 Esch JJ, Shah PB, Cockrill BA. , et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant 2013; 32 (04) 381-387
    CrossrefPubMedGoogle Scholar
  • 68 Salna M, van Boxtel B, Rosenzweig EB, Bacchetta M. Modified Potts shunt in an adult with idiopathic pulmonary arterial hypertension. Ann Am Thorac Soc 2017; 14 (04) 607-609
    CrossrefPubMedGoogle Scholar
  • 69 Xu Z, Owens G, Gordon D, Cain C, Ludomirsky A. Noninvasive creation of an atrial septal defect by histotripsy in a canine model. Circulation 2010; 121 (06) 742-749
    CrossrefPubMedGoogle Scholar
  • 70 Kula S, Atasayan V. Surgical and transcatheter management alternatives in refractory pulmonary hypertension: Potts shunt. Anatol J Cardiol 2015; 15 (10) 843-847
    CrossrefPubMedGoogle Scholar
  • 71 Punnoose L, Burkhoff D, Rich S, Horn EM. Right ventricular assist device in end-stage pulmonary arterial hypertension: insights from a computational model of the cardiovascular system. Prog Cardiovasc Dis 2012; 55 (02) 234-243.e2
    CrossrefPubMedGoogle Scholar
  • 72 Mauritz GJ, Marcus JT, Westerhof N, Postmus PE, Vonk-Noordegraaf A. Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart 2011; 97 (06) 473-478
    CrossrefPubMedGoogle Scholar
  • 73 Rasmussen JT, Thenappan T, Benditt DG, Weir EK, Pritzker MR. Is cardiac resynchronization therapy for right ventricular failure in pulmonary arterial hypertension of benefit?. Pulm Circ 2014; 4 (04) 552-559
    CrossrefPubMedGoogle Scholar
  • 74 Hardziyenka M, Surie S, de Groot JR. , et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace 2011; 13 (12) 1753-1759
    CrossrefPubMedGoogle Scholar
  • 75 Berruezo A, De Potter T, Sitges M, Mansour F, Mont L, Brugada J. Bifocal right ventricular resynchronization for the failing right ventricle. Pacing Clin Electrophysiol 2011; 34 (08) e78-e81
    CrossrefPubMedGoogle Scholar
  • 76 Bando K, Armitage JM, Paradis IL. , et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994; 108 (06) 1056-1065
    PubMedGoogle Scholar
  • 77 Gammie JS, Keenan RJ, Pham SM. , et al. Single- versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1998; 115 (02) 397-402 , discussion 402–403
    CrossrefPubMedGoogle Scholar
  • 78 Conte JV, Borja MJ, Patel CB, Yang SC, Jhaveri RM, Orens JB. Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 2001; 72 (05) 1673-1679 , discussion 1679–1680
    CrossrefPubMedGoogle Scholar
  • 79 Christie JD, Kotloff RM, Pochettino A. , et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124 (04) 1232-1241
    CrossrefPubMedGoogle Scholar
  • 80 King RC, Binns OA, Rodriguez F. , et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69 (06) 1681-1685
    CrossrefPubMedGoogle Scholar
  • 81 Kuntz CL, Hadjiliadis D, Ahya VN. , et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant 2009; 23 (06) 819-830
    CrossrefPubMedGoogle Scholar
  • 82 Shah RJ, Diamond JM, Cantu E. , et al. Objective estimates improve risk stratification for primary graft dysfunction after lung transplantation. Am J Transplant 2015; 15 (08) 2188-2196
    CrossrefPubMedGoogle Scholar
  • 83 Pérez-Terán P, Roca O, Rodríguez-Palomares J. , et al. Influence of right ventricular function on the development of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2015; 34 (11) 1423-1429
    CrossrefPubMedGoogle Scholar
  • 84 Armstrong HF, Schulze PC, Kato TS, Bacchetta M, Thirapatarapong W, Bartels MN. Right ventricular stroke work index as a negative predictor of mortality and initial hospital stay after lung transplantation. J Heart Lung Transplant 2013; 32 (06) 603-608
    CrossrefPubMedGoogle Scholar
  • 85 Pérez-Terán P, Roca O, Rodríguez-Palomares J. , et al. Prospective validation of right ventricular role in primary graft dysfunction after lung transplantation. Eur Respir J 2016; 48 (06) 1732-1742
    CrossrefPubMedGoogle Scholar
  • 86 Liu Y, Liu Y, Su L, Jiang SJ. Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis. PLoS One 2014; 9 (03) e92773
    CrossrefPubMedGoogle Scholar
  • 87 Herve P, Humbert M, Sitbon O. , et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22 (03) 451-458
    CrossrefPubMedGoogle Scholar
  • 88 Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12 (06) 1446-1449
    CrossrefPubMedGoogle Scholar
  • 89 Ritchie ME, Dávila-Román VG, Barzilai B. Dynamic right ventricular outflow obstruction after single-lung transplantation. Biplane transesophageal echocardiographic findings. Chest 1994; 105 (02) 610-611
    CrossrefPubMedGoogle Scholar
  • 90 Porteous MK, Ky B, Kirkpatrick JN. , et al. Diastolic dysfunction increases the risk of primary graft dysfunction after lung transplant. Am J Respir Crit Care Med 2016; 193 (12) 1392-1400
    CrossrefPubMedGoogle Scholar
  • 91 Yusen RD, Edwards LB, Kucheryavaya AY. , et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34 (10) 1264-1277
    CrossrefPubMedGoogle Scholar
  • 92 Sato M, Waddell TK, Wagnetz U. , et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30 (07) 735-742
    CrossrefPubMedGoogle Scholar
  • 93 Lau EM, Manes A, Celermajer DS, Galiè N. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J 2011; 32 (20) 2489-2498
    CrossrefPubMedGoogle Scholar